These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7576985)

  • 1. First experience with prognostic factors in unselected neuroblastoma patients. The Austrian Neuroblastoma 87 Study.
    Ladenstein R; Urban C; Gadner H; Fink FM; Zoubek A; Emminger W; Grienberger H; Schmitt K; Ambros PF; Ambros IM
    Eur J Cancer; 1995; 31A(4):637-41. PubMed ID: 7576985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
    Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
    Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma in southern Africa: epidemiological features, prognostic factors and outcome.
    Hesseling PB; Ankone K; Wessels G; Schneider JW; Du Plessis L; Moore S
    Ann Trop Paediatr; 1999 Dec; 19(4):357-63. PubMed ID: 10716030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.
    Zeltzer PM; Marangos PJ; Evans AE; Schneider SL
    Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
    Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
    J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factor in neuroblastoma.
    Evans AE; D'Angio GJ; Propert K; Anderson J; Hann HW
    Cancer; 1987 Jun; 59(11):1853-9. PubMed ID: 3567848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma: a single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors.
    Lau L
    Pediatr Hematol Oncol; 2002 Mar; 19(2):79-89. PubMed ID: 11881792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
    Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
    J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuron-specific enolase evaluation in patients with neuroblastoma.
    Massaron S; Seregni E; Luksch R; Casanova M; Botti C; Ferrari L; Martinetti A; Molteni SN; Bellani FF; Bombardieri E
    Tumour Biol; 1998; 19(4):261-8. PubMed ID: 9679736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age.
    Berthold F; Hero B; Kremens B; Handgretinger R; Henze G; Schilling FH; Schrappe M; Simon T; Spix C
    Cancer Lett; 2003 Jul; 197(1-2):11-7. PubMed ID: 12880954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.